Letters sent to healthcare professionals in November 2017

Letters were sent about eluxadoline (Truberzi), fingolimod (Gilenya), Bleo-Kyowa (bleomycin sulphate), Buccolam (midazolam), and ERWINASE.

• From: Medicines and Healthcare products Regulatory Agency
• Published: 14 December 2017

• Therapeutic area: Cancer, Dentistry, GI, hepatology and pancreatic disorders, Haematology and Neurology

In November 2017, the following letters were sent to relevant healthcare professionals to inform them of updated safety information:

• Eluxadoline (Truberzi ▼): risk of pancreatitis and sphincter of Oddi spasm

• Fingolimod (Gilenya▼): contraindications in patients with cardiac conditions

• Bleo-Kyowa (bleomycin sulphate), powder for solution for injection – use 5-micron filter during IV infusion or pre-injection – see Caution in Use alert

• Buccolam (midazolam) prefilled plastic syringes: potential product defect – see Caution in Use alert

• ERWINASE: notice of special handling instructions—vials of ERWINASE from batch 185G* should be used with a 5-micron filter needle

Article citation: Drug Safety Update volume 11, issue 5; December 2017: 7.

Published 14 December 2017